Neurofibromatosis News

Neurofibromatosis Research: Early-phase trial demonstrates shrinkage in pediatric neural tumors

Posted on
Health Medical Breakthroughs Treatment

(SOURCE: NATIONAL CANCER INSTITUTE) – In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage. NF1 affects 1 in 3,000 people. The study results appeared […]